This study is testing the safety and effectiveness of a higher dose (8mg) of an existing eye injection medicine called aflibercept. It aims to control a severe form of diabetic eye disease called proliferative diabetic retinopathy (PDR) in 40 patients over two years. The goal is …
Phase: PHASE4 • Sponsor: Edward Wood, MD • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC